clinical trial · NCT07100925
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Ankyra Therapeutics, Inc·phase1·not yet recruiting·n = 20
Cutaneous Squamous Cell Carcinoma (CSCC)Renal TransplantSolid TumorSolid Tumor Cancertolododekin alfa
brief summary
A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).
started
Dec 15, 2025
primary completion
Jun 1, 2030
completion
Dec 1, 2030
last updated
Aug 3, 2025
official title
An Open-Label Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With Resectable, High-Risk Cutaneous Squamous Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol